PDCD1 and hepatocellular carcinoma: In particular, about 54% of HCC cases were associated with hepatitis B virus (HBV) infection [10], and HCC patients with HBV infection were excluded in early anti-PD-1 therapy trials due to concerns about the reactivation of HBV and uncertain about immune microenvironment.